← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #884 OF 1,000 MOST-CITED

Raw material control - Inspection

FDA cited this observation 16 times across 15 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods16
BY FISCAL YEAR
FY20263
FY20254
FY20245
FY20233
FY20221

How FDA worded it — real examples

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

Recaito Mi Campo Corp. · Canovanas, Puerto Rico · Foods · 2026-04-20

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

GTX Technologies · Amarillo, Texas · Foods · 2026-01-29

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

Gina Marie Bakery LLC · Waterbury, Connecticut · Foods · 2025-12-01

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

Rudy's Inflight Catering, Inc · White Plains, New York · Foods · 2025-04-21

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

Bake Shop, LLC · Brenham, Texas · Foods · 2025-03-26

You did not inspect, segregate or otherwise handle raw materials and other ingredients to ensure they were clean and suitable for processing.

Middle East/ Soli's Baking Company, Inc. dba Middle East Baking Co. · Burlingame, California · Foods · 2025-01-10

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Food industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →